Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MIRA PHARMACEUTICALS, INC. (MIRA)

MIRA Pharmaceuticals reports mouse study showing SKNY-1 weight and fat reduction

Neutral Impact 2 of 5 other Written later

MIRA Pharmaceuticals announced initial results from an exploratory preclinical pilot study of SKNY-1, its oral obesity drug candidate, in diet-induced obese mice. The study reported statistically significant reductions in body weight and fat mass versus vehicle controls, and compared SKNY-1 with semaglutide on food intake, lean mass, and weight regain, but these are early animal results with no financial figures disclosed.

Key points

  • Oral SKNY-1 produced statistically significant reductions in body weight and fat mass versus vehicle-treated mice in a diet-induced obesity model.
  • At Day 14, SKNY-1 mice showed no statistically significant lean-mass loss, while semaglutide mice showed statistically significant lean-mass loss.
  • During a two-week observation period after treatment stopped, SKNY-1 mice showed slow, limited weight regain, versus rapid rebound with semaglutide.
  • The press release is dated October 29, 2026; the company says its next study will measure energy expenditure and metabolic parameters.

The filing

CompanyMIRA PHARMACEUTICALS, INC. (MIRA)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:01 PM ET
Accession number0001493152-26-048978

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.